Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,460 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Newborn Complication Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Micronized progesterone, Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 13, 2026, 5:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational

Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

NCT03782610
View directory record Official record
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia, Neurodevelopmental Abnormality
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 72 Hours
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Thromboelastography (TEG) In the Intrauterine Growth Restriction (IUGR) Neonatal Population by Gestational Age

NCT04907578
View directory record Official record
Conditions
Intrauterine Growth Restriction
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 13, 2026, 5:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT03160274
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
Interventions
Genetic screening
Genetic
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

NCT00519818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
Interventions
Chronocort, Cortef
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

NCT00406926
View directory record Official record
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2006 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

VasQ External Support for Arteriovenous Fistula

NCT03242343
View directory record Official record
Conditions
Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm, Renal Failure, Renal Disease, Diabetes Mellitus, Kidney Failure
Interventions
VasQ
Device
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Peoria, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Comparison of Primary Extubation Failure Between NIPPV and NI-NAVA

NCT03242057
View directory record Official record
Conditions
Preterm Infant, BPD - Bronchopulmonary Dysplasia, Barotrauma
Interventions
NAVA, NIPPV
Other
Lead sponsor
University of Florida
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 13, 2026, 5:19 AM EDT
Not listed No phase listed Observational

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

NCT05419245
View directory record Official record
Conditions
Freeman-Burian Syndrome, Freeman-Sheldon Syndrome, Whistling Face Syndrome, Sheldon-Hall Syndrome, Freeman-Sheldon Syndrome Variant, Arthrogryposis Distal Type 1, Arthrogryposis Distal Type 3, Gordon Syndrome
Interventions
Guided Health History for Freeman-Burian Syndrome Questionnaire, Freeman-Burian syndrome Semi-Structured Quality of Life Interview, Medical Records Review, PTSD Checklist for DSM-5, Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale, Review of Systems, FACE-Q | Craniofacial - Appearance of the Face, FACE-Q | Craniofacial - Appearance Distress, FACE-Q | Craniofacial - Facial Function
Other
Lead sponsor
Dufresne, Craig, MD, PC
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Completed No phase listed Observational

Cystine Capacity Clinical Study (CysCap)

NCT02120105
View directory record Official record
Conditions
Cystinuria
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
8 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 13, 2026, 5:19 AM EDT
Not listed Not applicable Interventional

Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?

NCT01944696
View directory record Official record
Conditions
Hyperbilirubinemia, Premature Newborns, Extremely Low Birth Weight
Interventions
phototherapy
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 24 Hours
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • Palo Alto, California • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 13, 2026, 5:19 AM EDT
Recruiting Early Phase 1 Interventional

Pencil Beam Scanning in Patients With Renal Tumors

NCT03810651
View directory record Official record
Conditions
Renal Tumor, Wilms Tumor
Interventions
Proton beam radiation using pencil beam scanning
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 30 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Completed No phase listed Observational

Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease

NCT01126372
View directory record Official record
Conditions
Congenital Heart Disease, Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 1 Month
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 13, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Prediabetes in the First Trimester

NCT01926457
View directory record Official record
Conditions
Prediabetes, Gestational Diabetes
Interventions
Treatment of Prediabetes
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 13, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional

Automated Insulin for Management of Intrapartum Glycemia

NCT06883344
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions
Automated insulin delivery (AID) system, Intravenous (IV) insulin
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

NCT00003107
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 13, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational

Dilapan-S®: A Multicenter US E-registry

NCT04451109
View directory record Official record
Conditions
Post Term Pregnancy, Premature Rupture of Membrane, Fetal Growth Retardation, Oligohydramnios, Gestational Diabetes, High Blood Pressure in Pregnancy
Interventions
Dilapan-S
Device
Lead sponsor
Medicem Technology s.r.o.
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 13, 2026, 5:19 AM EDT
Completed No phase listed Observational

Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus

NCT03551600
View directory record Official record
Conditions
Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
Interventions
Near-infrared spectroscopy (NIRS)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
12 Days to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 13, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

NCT00000665
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 13, 2026, 5:19 AM EDT
Recruiting Phase 2 Interventional

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

NCT07104812
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions
Osilodrostat 1 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 13, 2026, 5:19 AM EDT